Clinical Trials

Valarie Higgins discusses how clinical trials have evolved over the years and the key lessons she has learned while building her career in the industry.

We must find ways to better help vaccine manufacturers to fight the flu – and this is why we developed a new challenge agent for H3N2.

New solutions are needed to teach the immune system to recognize biological drugs as partners rather than plunderers.

Artificial intelligence could have a huge impact on drug discovery.

The path to market for a biosimilar involves an abbreviated approval process, focused on proving “biosimilarity”.

Rare diseases aren’t the only field that can benefit from repurposing – the eye is also often overlooked.

New data protection regulations are coming.

Researchers develop a new way to tackle pain: inhibition of RNA-protein interactions.

A review of FDA data suggests that women are now better represented in clinical trials.

Publishing negative results might not flatter – but it does matter.